Daré Bioscience is a women's health biotech company developing and commercializing evidence-based solutions across contraception, sexual health, menopause, pelvic pain, and infectious disease. The company employs a dual-path strategy combining traditional FDA-approved products with faster market access through Section 503B compounded prescriptions and consumer health offerings, using outsourced manufacturing and distribution to minimize capital requirements. Its portfolio includes marketed products such as XACIATO (an FDA-approved bacterial vaginosis gel licensed globally to Organon), near-term compounded offerings including topical sildenafil cream and vaginal probiotics, and a clinical-stage pipeline spanning contraceptives, hormone therapies, and treatments for underserved conditions with limited existing options, while leveraging non-dilutive federal grants and partnerships to advance development.